三联抗肿瘤疗法预防晚期原发性肝癌肝移植术后肿瘤复发的临床研究

Clinical study of triple anti-tumor therapy for preventing tumor recurrence of terminal primary liver cancer after liver transplantation

  • 摘要:
      目的   初步探讨联合应用西罗莫司、胸腺肽α-1(Tα-1)及槐耳颗粒在预防晚期原发性肝癌(肝癌)肝移植术后肿瘤复发的有效性及安全性。
      方法   联合治疗组为2010年至2012年在解放军第309医院接受肝移植的12例晚期肝癌患者(符合杭州标准)。历史对照组为2002年至2006年在该院接受晚期肝癌肝移植术15例患者,其随访资料完整。术后1个月根据患者的个体差异调整免疫抑制剂的种类或剂量,应用他克莫司(FK506)联合吗替麦考酚酯(MMF),术后1个月逐渐撤出FK506,由西罗莫司替代;术中给予甲泼尼龙500 mg,术后小剂量甲泼尼龙治疗,1周停药,此时开始加用Tα-1及槐耳颗粒。Tα-1用法:先连续皮下注射10 d,每次1.6 mg,每日1次,以后每周2次。槐耳颗粒:每次20 g,每日3次。所有患者均予随访。收集患者术后随访资料,内容包括术后1年血清甲胎蛋白(AFP)变化,术后排斥反应发生情况,肿瘤复发情况及处理方式,生存时间。
      结果   联合治疗组随访8~35个月,中位随访时间18个月,无失访、退组等情况,患者均存活;历史对照组中位随访时间14个月,直至所有患者死亡。联合治疗中2例术后出现肺部孤立性转移灶(单发)和2例术后出现肺部多发转移灶(多发),经γ刀治疗后治愈。历史对照组中术后6个月15例患者中7例复发,术后1年内15例患者全部复发,且全部出现肺部转移,单发6例,多发9例,均死于肿瘤多处转移。
      结论   联合应用西罗莫司、Tα-1及槐耳颗粒在预防晚期肝癌肝移植术后肿瘤复发有显著疗效,能延缓肿瘤的复发,延长患者的生存时间。

     

    Abstract:
      Objective   To investigate initially the availability and safety of combined application of sirolimus, thymosin α-1(Tα-1) and Huaier granule in preventing tumor recurrence of terminal primary liver cancer(TPLC) after liver transplantation(LT).
      Methods   Combination group included 12 patients with TPLC who underwent LT in the 309th hospital of Chinese People's Liberation Army from 2010 to 2012(all conform to Hangzhou standard). And historical control group included 15 patients with TPLC underwent LT at the same hospital from 2002 to 2006, whose follow up data was true and precise. During 1 month after LT, the type or dose of immunosuppressors was adjusted according to the individual differences of patients. Tacrolimus(FK506) and mycophenolate mofetil(MMF) were given to patients at first, and FK506 was gradually withdrawn and insteaded by sirolimus at 1 month after LT. Methylprednisolone of 500 mg was given during operation. Then small dose of methylprednisolone was given after operation and withdrawn at 1 week after LT. At the same time Tα-1 and Huaier Granule were added. The Tα-1 was injected for 10 days(1.6 mg per time, once a day), and after that injected twice a week. Huaier granule was given 20 g per time and three times a day. All the patients had been followed up. All the data including serum alpha-fetoprotein(AFP) changes, occurrence of allograft rejection, recurrence and treatment, survival time were collected accurately.
      Results   In the combination group, the 12 cases were followed up for 8-35 months with the median follow up time of 18 months without loss or drop-out. All patients were survived. In the historical control group, the medium follow up time was 14 months till all the patients died. In the combination group, 2 cases developed isolated pulmonary metastasis after LT and 2 cases deveoped multiple pulmonary metastasis. All of the four cases were cured with the treatment of γ-knife. In history control group, 7 cases developed recurrence in 6 months after LT and all of the 15 cases developed recurrence in 1 year after LT. All of the 15 cases developed pulmonary metastasis(6 cases were isolated and 9 cases were multiple). All cases died of multi-section of tumor metastasis.
      Conclusions   Combined application of sirolimus, Tα-1 and Huaier granule have significantly effect on preventing tumor recurrence of TPLC after LT, delaying tumor recurrence and prolonging survival time of patients.

     

/

返回文章
返回